Great Point Partners LLC Has Trimmed Its Synergy Pharmaceuticals Del (SGYP) Stake by $7.90 Million as Stock Value Declined

March 14, 2018 - By Marie Mckinney

Investors sentiment increased to 1.9 in Q3 2017. Its up 0.41, from 1.49 in 2017Q2. It increased, as 16 investors sold SGYP shares while 23 reduced holdings. 21 funds opened positions while 53 raised stakes. 147.06 million shares or 7.33% less from 158.68 million shares in 2017Q2 were reported. 21,381 were accumulated by Cubist Systematic Strategies Llc. 158,400 are held by Knott David M. Qci Asset Management owns 2,500 shares for 0% of their portfolio. State Treasurer State Of Michigan reported 0% stake. Tudor Inv Et Al invested in 0% or 63,768 shares. Moreover, Ubs Asset Mngmt Americas has 0% invested in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) for 80,394 shares. Geode Capital Mgmt Lc stated it has 0% of its portfolio in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP). Rhumbline Advisers holds 259,408 shares or 0% of its portfolio. Wells Fargo & Com Mn stated it has 219,676 shares. Goldman Sachs invested in 0% or 3.32 million shares. Legal & General Gru Public Limited Com reported 0% of its portfolio in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP). Texas-based Teacher Retirement Systems Of Texas has invested 0% in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP). Orbimed Advisors Limited Liability has invested 0.38% in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP). D E Shaw invested 0% in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP). Ameritas Invest Prtnrs holds 0% or 19,906 shares.

Jeffrey Jay decreased its stake in Synergy Pharmaceuticals Del (SGYP) by 54.68% based on its latest 2017Q3 regulatory filing with the SEC. Great Point Partners Llc sold 3.95M shares as the company’s stock declined 35.42% while stock markets rallied. The hedge fund run by Jeffrey Jay held 3.27M shares of the health care company at the end of 2017Q3, valued at $9.49 million, down from 7.22 million at the end of the previous reported quarter. Great Point Partners Llc who had been investing in Synergy Pharmaceuticals Del for a number of months, seems to be less bullish one the $515.52M market cap company. The stock decreased 0.48% or $0.01 during the last trading session, reaching $2.09. About 1.76M shares traded. Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) has risen 24.44% since March 14, 2017 and is uptrending. It has outperformed by 7.74% the S&P500.

Analysts await Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) to report earnings on May, 9. They expect $-0.16 EPS, up 46.67 % or $0.14 from last year’s $-0.3 per share. After $-0.18 actual EPS reported by Synergy Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts -11.11 % EPS growth.

More notable recent Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) news were published by: which released: “Synergy Pharma: Important Numbers” on February 26, 2018, also with their article: “SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Synergy …” published on February 21, 2018, published: “Synergy Pharmaceuticals: Q4 Earnings Highlights” on March 02, 2018. More interesting news about Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) were released by: and their article: “Synergy Pharmaceuticals’ Cash Flow And Prescription Trends” published on March 08, 2018 as well as‘s news article titled: “Investor Alert: Kaplan Fox Announces Investigation Of Synergy Pharmaceuticals Inc.” with publication date: February 24, 2018.

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) Ratings Coverage

Among 8 analysts covering Synergy Pharmaceuticals (NASDAQ:SGYP), 6 have Buy rating, 1 Sell and 1 Hold. Therefore 75% are positive. Synergy Pharmaceuticals had 42 analyst reports since August 25, 2015 according to SRatingsIntel. Oppenheimer maintained Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) on Tuesday, October 10 with “Buy” rating. Cantor Fitzgerald initiated Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) rating on Thursday, June 1. Cantor Fitzgerald has “Buy” rating and $1100 target. Oppenheimer maintained the stock with “Hold” rating in Monday, January 22 report. The rating was maintained by H.C. Wainwright on Wednesday, October 18 with “Buy”. The stock of Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) has “Perform” rating given on Friday, January 5 by Oppenheimer. The rating was maintained by H.C. Wainwright with “Buy” on Monday, September 25. The firm has “Buy” rating given on Thursday, January 25 by Canaccord Genuity. Canaccord Genuity maintained the shares of SGYP in report on Friday, November 10 with “Buy” rating. The firm earned “Buy” rating on Friday, December 23 by Rodman & Renshaw. As per Wednesday, March 16, the company rating was maintained by Citigroup.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: